1477.HK
Ocumension Therapeutics [1477.HK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
1477.HK Stock Summary
Top 10 Correlated ETFs
1477.HK
Top 10 Correlated Stocks
1477.HK
In the News
1477.HK Financial details
Company Rating
-
Market Cap
3.97B
Income
-418.38M
Revenue
208.12M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
444
Optionable
No
Shortable
Yes
Earnings
21 Mar 2024
P/E
-8.85
Forward P/E
-
PEG
-0.46
P/S
23.8
P/B
1.3
P/C
-
P/FCF
-7.41
Quick Ratio
5.76
Current Ratio
5.88
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.64
EPS next Y
-
EPS next Q
-
EPS this Y
190.91%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
4.16%
SMA50
26.44%
SMA100
-0.94%
Inst Own
-
Inst Trans
-
ROA
-13%
ROE
-14%
ROC
-0.14%
Gross Margin
65%
Oper. Margin
-250%
Profit Margin
-253%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.51-10.4
52W High
-45.8%
52W Low
+35.5%
RSI
61.42
Rel Volume
2.7
Avg Volume
653.66K
Volume
1.76M
Perf Week
13.63%
Perf Month
10.16%
Perf Quarter
-1.45%
Perf Half Y
-6.55%
-
-
-
-
Beta
0.925
-
-
Volatility
0.16%, 0.34%
Prev Close
0%
Price
5.42
Change
0%
Company Profile
- Volume Average 653.66K
- Market Capitalization 3.97B
- Employee 444
- CEO Mr. Ye Liu
- Headquarters Suzhou,CN
- IPO Date 2020-07-10
-
Website
https://www.ocumension.com 
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company discovers, develops, and commercializes therapies for ophthalmic patients. It offers drugs for the treatment of blepharitis, infective and allergic conjunctivitis, dry eye, cataract, glaucoma and ocular hypertension, postoperative inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. As of December 31, 2021, the company had 20 drug assets in its portfolio. Ocumension Therapeutics was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.
